原发性皮肤弥漫大B细胞淋巴瘤（腿型）一例

报告1例原发性皮肤弥漫性大B细胞淋巴瘤（腿型）。患者男,51岁。右小腿出现多个红色结节5个月,组织病理检查：表皮和真皮之间见无细胞浸润带,真皮内淋巴样细胞浸润,细胞体积大,异形。肿瘤细胞CD20（++）,Bcl-6(+),Bcl-2(+),Pax-5(+),Ki-67 50％-75％(+),CD79a(+),MUM-1（+）,CD10（-）,诊断为原发性皮肤弥漫性大B细胞淋巴瘤（腿型）,给予CD20单克隆抗体加CHOP方案治疗,病情好转。     

原发性皮肤CD30+间变性大细胞淋巴瘤1例及文献复习

报告1例原发性皮肤CD30+间变性大细胞淋巴瘤。患者男,73岁。右上肢红色丘疹伴溃疡1年余。皮肤科检查：右上肢邻近腋窝外侧可见数个圆形或类圆形红色丘疹,边界清晰,部分融合成片状,皮损中央破溃、结痂,其间可见色素沉着及瘢痕形成,质稍硬。皮损组织病理检查：真皮全层大量异形淋巴细胞弥漫浸润,核大深染,可见核分裂象。免疫组化：CD30强阳性,CD2、CD4、CD43、MUM-1及TIA-1均阳性,Granzyme B（部分细胞阳性）,增殖核抗原（Ki-67）（约80%阳性）,CD20、CD79a、CD56、BCL-2、BCL-6及CD10均阴性。EB病毒编码小RNA(EBER)原位杂交阴性。诊断：原发性皮肤CD30+间变性大细胞淋巴瘤。     

原发性皮肤弥漫大B细胞淋巴瘤,腿型

报告1例原发性皮肤弥漫性大B细胞淋巴瘤（腿型）。患者女，82岁。左小腿出现3个红色结节2个月，组织病理检查发现真皮内淋巴样细胞浸润，无嗜表皮现象，细胞体积大，肿瘤细胞CD20（＋），CD79α（＋），Bcl-2（＋），Bcl-6（＋），Ki-67 70％（＋），MUM-1（＋），Pax-5（＋），CD10（-），诊断为原发性皮肤弥漫性大B细胞淋巴瘤（腿型），全身检查未发现皮肤以外系统受累证据，行局部肿瘤切除及口服糖皮质激素治疗。     

鼻NK/T细胞淋巴瘤1例

报道1例以皮肤为首发症状的鼻NK／T细胞淋巴瘤。患者男，48岁。双下肢、躯干、双上肢陆续出现红色斑丘疹、结节及溃疡4月余，鼻腔发现新生物1月余。皮肤及鼻部组织病理示中、小淋巴样细胞弥漫浸润；免疫组化染色：CD56（＋），LCA（＋），UCLH－1（＋），26(-),CD57(-);EBER( )。     

原发性皮肤间变性大细胞淋巴瘤一例

［摘要］报告1例原发性皮肤CD30+大细胞性淋巴瘤。右前臂皮肤红肿浸润、溃疡结痂1月,左侧头面部红肿浸润10天。右前臂皮损组织病理检查：真皮深层以及皮下脂肪组织间瘤细胞浸润,密集分布。瘤细胞胞质丰富,呈嗜酸性,部分呈空泡状,细胞核大,异型性明显,核仁明显,染色质呈粗颗粒状,并可见病理性核分裂象;有少量成熟淋巴细胞浸润。行免疫组化检查示： 瘤细胞CD45R0（+）、CD30（+）,CD68（－）、CD20（-）、EMA（-）及ALK（-）。诊断为原发性皮肤间变性大细胞淋巴瘤     

第三讲原发性皮肤大细胞淋巴瘤的分类

原发性皮肤大细胞淋巴瘤（PCLC）可分为T细胞性和B细胞性两类。T细胞表型PCLCL[PCLCL(T)]可以CD30阳性与否预期其预后。CD30^＋PCLCL(T)和CD30^ 非皮肤原发性LCL（T）的预后差。从蕈样肉芽肿转化成的CD30^ 皮肤LCL的预后一般差，从淋巴瘤样丘疹病演变成的CD30^ -LCL仅系统性的预后差而皮肤CD30^ -LCL的预后则不差。原发性皮肤多形T细胞性淋巴瘤，大细胞型和原发性皮肤T－免疫母细胞性淋巴瘤的预后差。B细胞表型原发性皮肤大细胞淋巴瘤中绝大多数为原发性皮肤滤泡中心细胞性淋巴瘤，其预后较淋巴结滤泡中心细胞性淋巴瘤为好。     

原发性皮肤弥漫性大B细胞淋巴瘤并发嗜酸性粒细胞增多

报告1例原发性皮肤弥漫性大B细胞淋巴瘤并发嗜酸性粒细胞增多.患者男,71岁.伞身散在红斑、丘疹及小结节,外周血嗜酸性粒细胞计数增多.第1次行皮损组织病理检查示嗜酸性粒细胞增多,予以精皮质激素治疗后皮损消退,但外周血嗜酸性粒细胞计数持续增多.发病近4个月,结节再次出现,第2次组织病理检查示真皮及皮下组织内弥漫淋巴细胞浸润,多数浸润细胞核大,染色深,核分裂象易见.免疫组化染色:大的肿瘤细胞CD20、CD79a、Bcl-2均(+).诊断:原发性皮肤弥漫性大B细胞淋巴瘤.给予环磷酰胺、长春地辛、呲喃阿霉素、泼尼松(CHOP)方案化疗后皮损改善不明显.     

下肢原发性皮肤弥漫大B细胞淋巴瘤

报告1例原发性皮肤弥漫大B细胞淋巴瘤。患者男，59岁。因右侧小腿肿块渐增大半年余就诊。皮损组织病理检查示：真皮全层可见大量淋巴细胞及少量组织细胞弥漫性浸润，并与表皮基底层之间有明显无浸润带；增生的淋巴细胞可见较多核分裂象，细胞异形明显。免疫组化染色示：〉30％的异形淋巴细胞CD20（＋），〉80％的异形淋巴细胞波形蛋白（＋）；CD3、CD68、CD34、CD45RO均（-）。采用放疗及化疗治疗，放疗总剂量为84Gy；化疗采用CHOP（环磷酰胺、长春新碱、多柔比星及泼尼松）方案，经过5次化疗后，疗效显著。     

原发性皮肤CD4+多形性小/中T细胞淋巴瘤1例临床病理观察并文献复习

报告1例原发性皮肤CD4 多形性小/中T细胞淋巴瘤.患者女,45岁.右膝右上方反复红斑、结节15年.组织病理检查示真皮全层及皮下脂肪层弥漫性结节性致密小到中等大淋巴样细胞浸润.细胞有异形,其间混杂少量炎性细胞,无亲表皮现象.免疫组化检查示全T抗原缺失的Th表型.诊断:原发性皮肤CD4 多形性小/中T细胞淋巴瘤.     

第五讲 B细胞-皮肤淋巴样增生

阐述B细胞-皮肤淋巴样增生的命名、临床表现、组织病理、免疫组织化学染色及其B-小淋巴细胞性淋巴瘤/慢性淋巴细胞性白血病、原发性皮肤滤泡中心细胞性淋巴瘤、原发性皮肤边缘区淋巴瘤等鉴别诊断和治疗。     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Self‐resolving superficial primary cutaneous mucormycosis in a 7‐week‐old infant

A 7‐week‐old girl, born at 30 weeks' gestational age, presented to clinic for evaluation of a crop of vesicular lesions that were noted after removal of a bandage that had been in place for 4 days. A punch biopsy of the lesion revealed fungal elements that were later identified as Rhizopus spp. The lesion began to self‐resolve, and no further treatment was needed, with full resolution of the lesion by 1 month after presentation. Clinicians should be aware of the variable presentations of mucormycosis and consider fungal infection in the differential diagnosis when evaluating vulnerable patients with skin eruptions.     

Multiple New-Onset Subcutaneous Nodules of the Upper Extremity Digits: Giant Cell Tumor of Tendon Sheath and Lipoma

A black woman with the concurrent onset of two subcutaneous nodules located on the digits of her upper extremities is described. Initially, a single systemic disorder was considered; yet, the lesions differed in morphology and consistency. Microscopic examination of the nodules showed a giant cell tumor of tendon sheath and a lipoma. Although Occam's “razor” suggests that multiple lesions in the same person are more likely to represent variable manifestations of a single disorder than several different diseases in that individual, the simultaneously appearing lesions in this patient represented two different conditions.